S Piha-Paul
Overview
Explore the profile of S Piha-Paul including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
121
Followers
0
Related Specialty
Related Specialty
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nelson B, Naing A, Fu S, Sheth R, Murthy R, Piha-Paul S
Immunooncol Technol
. 2025 Feb;
25:101040.
PMID: 39981134
Immune checkpoint inhibitors (ICIs) have revolutionized oncology, yielding remarkable and durable responses in various cancers. However, a significant proportion of patients develop resistance to ICIs. The tumor microenvironment plays a...
2.
Dumbrava E, Brusco L, Daniels M, Wathoo C, Shaw K, Lu K, et al.
JCO Precis Oncol
. 2019 Sep;
3.
PMID: 31517177
Background: Next-generation sequencing (NGS) for tumor molecular profiling can reveal secondary germline pathogenic and likely pathogenic variants (LPV/PV). The American College of Medical Genetics (ACMG) recommends return of secondary results...
3.
Fu S, Hirte H, Welch S, Ilenchuk T, Lutes T, Rice C, et al.
Invest New Drugs
. 2017 Apr;
35(3):397.
PMID: 28389981
No abstract available.
4.
Fu S, Hirte H, Welch S, Ilenchuk T, Lutes T, Rice C, et al.
Invest New Drugs
. 2017 Feb;
35(3):324-333.
PMID: 28150073
Introduction This was an open-label, dose escalation (3 + 3 design), Phase I study of SOR-C13 in patients with advanced tumors of epithelial origin. Primary objectives were to assess safety/tolerability...
5.
Henary H, George G, Wheler J, Naing A, Piha-Paul S, Fu S, et al.
Cancer Chemother Pharmacol
. 2015 Jul;
76(3):597-603.
PMID: 26210681
Purpose: Preclinically, pazopanib/lapatinib combination acted synergistically to suppress the activity of multiple tyrosine kinases, including VEGFR-1, 2, 3, PDGFR and c-kit (pazopanib), HER1/EGFR and HER2 (lapatinib), and several other tyrosine...
6.
Fu S, Hou M, Naing A, Janku F, Hess K, Zinner R, et al.
Ann Oncol
. 2015 Feb;
26(5):1012-1018.
PMID: 25669829
Background: We carried out a phase I trial of the vascular endothelial growth factor inhibitor pazopanib and the histone deacetylase inhibitor vorinostat to determine the safety and efficacy. Because these...
7.
Said R, Banchs J, Wheler J, Hess K, Falchook G, Fu S, et al.
Ann Oncol
. 2013 Dec;
25(1):276-82.
PMID: 24356639
Background: New targeted agents may cause acute cardiac events. The purpose of our study was to investigate the incidence and the prognostic significance of left ventricular ejection fraction (LVEF) in...
8.
Veasey Rodrigues H, Baracos V, Wheler J, Parsons H, Hong D, Naing A, et al.
Eur J Cancer
. 2013 Jul;
49(15):3068-75.
PMID: 23867127
Purpose: Delineate the relationships between body composition parameters, 90-day mortality and overall survival, and correlate them with known prognostic factors in an early clinical trials clinic. Patients And Methods: We...
9.
Henary H, Hong D, Falchook G, Tsimberidou A, George G, Wen S, et al.
Ann Oncol
. 2013 Apr;
24(8):2158-65.
PMID: 23576709
Background: The purpose of the study was to assess the outcome of patients with advanced melanoma treated with matched molecularly targeted therapy. Patients And Methods: We reviewed 160 consecutive patients...